We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Atara Reports Initial Data for Multiple Sclerosis Candidate
Read MoreHide Full Article
Atara Biotherapeutics, Inc. (ATRA - Free Report) announced initial ATA188 phase I safety results for patients with progressive multiple sclerosis (MS) at the 5th Congress of the European Academy of Neurology (EAN) in Oslo, Norway. The primary objective of the ongoing ATA188 phase I, dose-escalating clinical study is to evaluate safety and tolerability for patients with progressive MS.
ATA188 is a T-cell immunotherapy targeting Epstein-Barr virus (EBV) antigens, believed to be important for the potential treatment of MS. MS is a chronic autoimmune, inflammatory disease that affects axons in the central nervous system (CNS).
Shares of the company have plunged 42.2% year to date against the industry’s growth of 5.7%.
Initial safety results, as of Apr 8, 2019, showed that the first three ATA188 dose cohorts were well tolerated, with no dose-limiting toxicities and no ≥3 grade treatment-related, treatment-emergent adverse events. The key secondary endpoints of the phase I study include measures of clinical improvement, such as expanded disability status scale (EDSS), MRI imaging and other clinical activity measures. The study is ongoing and aims to identify a recommended phase II dose (RP2D). Further, a phase Ib extension period for this study, using the RP2D, is now planned following the completion of the open-label, dose-escalation period.
MS is a crowded market, with many companies already having drugs in their portfolio approved for this indication. Biogen, Inc. (BIIB - Free Report) holds a strong position in this market with a wide range of products, including Avonex, Tysabri, Tecfidera and Plegridy. In March, swiss pharma giant Novartis AG (NVS - Free Report) received FDA approval for its pipeline candidate Mayzent (siponimod), a next generation, selective sphingosine 1-phosphate receptor modulator, for the treatment of adults with relapsing forms of MS. Also Celgene’s ozanimod, being developed for the treatment of people with relapsing forms of MS, is under review in the United States and Europe.
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Atara Reports Initial Data for Multiple Sclerosis Candidate
Atara Biotherapeutics, Inc. (ATRA - Free Report) announced initial ATA188 phase I safety results for patients with progressive multiple sclerosis (MS) at the 5th Congress of the European Academy of Neurology (EAN) in Oslo, Norway. The primary objective of the ongoing ATA188 phase I, dose-escalating clinical study is to evaluate safety and tolerability for patients with progressive MS.
ATA188 is a T-cell immunotherapy targeting Epstein-Barr virus (EBV) antigens, believed to be important for the potential treatment of MS. MS is a chronic autoimmune, inflammatory disease that affects axons in the central nervous system (CNS).
Shares of the company have plunged 42.2% year to date against the industry’s growth of 5.7%.
Initial safety results, as of Apr 8, 2019, showed that the first three ATA188 dose cohorts were well tolerated, with no dose-limiting toxicities and no ≥3 grade treatment-related, treatment-emergent adverse events. The key secondary endpoints of the phase I study include measures of clinical improvement, such as expanded disability status scale (EDSS), MRI imaging and other clinical activity measures. The study is ongoing and aims to identify a recommended phase II dose (RP2D). Further, a phase Ib extension period for this study, using the RP2D, is now planned following the completion of the open-label, dose-escalation period.
MS is a crowded market, with many companies already having drugs in their portfolio approved for this indication. Biogen, Inc. (BIIB - Free Report) holds a strong position in this market with a wide range of products, including Avonex, Tysabri, Tecfidera and Plegridy. In March, swiss pharma giant Novartis AG (NVS - Free Report) received FDA approval for its pipeline candidate Mayzent (siponimod), a next generation, selective sphingosine 1-phosphate receptor modulator, for the treatment of adults with relapsing forms of MS. Also Celgene’s ozanimod, being developed for the treatment of people with relapsing forms of MS, is under review in the United States and Europe.
Zacks Rank
Atara currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>